Barrington analyst Michael Petusky raised the firm’s price target on U.S. Physical Therapy to $124 from $116 and keeps an Outperform rating on the shares following the “solid” Q2 report. The $1.15 decline in revenue per visit to $102.03 versus a year ago was likely the biggest source of investor concern for investors post the results, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on USPH:
- U.S. Physical Therapy reports Q2 EPS 64c, consensus 75c
- U.S. Physical Therapy acquires 70% stake in five clinic practice for $2.1M
- USPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- U.S. Physical Therapy management to meet virtually with Barrington
- U.S. Physical Therapy initiated with a Buy at BofA
